2017-064 – Rocky Mountain Spotted Fever Canine Vaccine

Researchers at Kansas State University have created an inactivated canine vaccine candidate to prevent Rocky Mountain Spotted Fever (RMSF) infection. RMSF is considered a biosecurity level 3 pathogen because it can infect humans. Kansas State University has the unique facilities and expertise to handle such a pathogen. Two vaccine candidates were created and tested in host animal studies: whole cell inactivated vaccine recombinant vaccine having two immunogenic proteins. Results: Dogs receiving the whole cell inactivated vaccine abated clinical signs completely and the pathogen from circulation. Dogs in the recombinant vaccine group did not show any obvious differences in clinical signs compared to non-vaccinated control group. These early results indicate the whole cell inactivated vaccine candidate could hold more promise for vaccine development and should be studied further. Bret Ford bretford@ksu.edu 785-532-3924

Related Blog

Smart, interactive desk

Get ready to take your space management game to the next level with the University of Glasgow’s innovative project! By combining the

Mechanical Hamstring™

University of Delaware Technology Overview This device was created to allow athletes who suffer a hamstring strain to return to the field

Join Our Newsletter

                                                   Receive Innovation Updates, New Listing Highlights And More